Silvia L Locatelli

Silvia L Locatelli

UNVERIFIED PROFILE

Are you Silvia L Locatelli?   Register this Author

Register author
Silvia L Locatelli

Silvia L Locatelli

Publications by authors named "Silvia L Locatelli"

Are you Silvia L Locatelli?   Register this Author

11Publications

133Reads

50Profile Views

YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.

Int J Cancer 2015 Jan 5;136(2):299-309. Epub 2014 Jun 5.

Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28993DOI Listing
January 2015

Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.

Clin Cancer Res 2014 Nov 19;20(22):5641-51. Epub 2014 Sep 19.

Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0770DOI Listing
November 2014

Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders.

FASEB J 2014 Feb 6;28(2):524-35. Epub 2013 Nov 6.

2Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanità, Rome, Italy.

View Article

Download full-text PDF

Source
http://www.fasebj.org/content/early/2013/11/05/fj.13-235655.
Web Search
http://www.fasebj.org/cgi/doi/10.1096/fj.13-235655
Publisher Site
http://dx.doi.org/10.1096/fj.13-235655DOI Listing
February 2014

Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.

PLoS One 2013 19;8(4):e61603. Epub 2013 Apr 19.

Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milano, Italy.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0061603PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631141PMC
November 2013

Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.

Angiogenesis 2013 Jul 20;16(3):707-22. Epub 2013 Apr 20.

Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Via Manzoni, 56, 20089 Rozzano, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10456-013-9348-7DOI Listing
July 2013